NF-κB can be activated by several different mechanisms in lung cancer and pre-neoplastic lesions driven by different oncogenes, carcinogens, mediators of inflammation and/or other mechanisms such as the crosstalk between NF-κB and the PI3K/Akt/mTOR pathway [28]. This evidence concerns the gene NFKB1 and lung carcinoma.